Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience [PDF]
Annals of HematologyEmicizumab is a FVIII mimetic antibody used in the treatment of inherited hemophilia A that could potentially be used in acquired hemophilia A (AHA) to achieve hemostasis and shorten hospital stay while reducing bypass therapies. We report on 12 cases of
Malcolm Su +3 more
doaj +2 more sources
Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Persons with hemophilia A (HA) and inhibitors undergoing emicizumab prophylaxis require bypassing agents when breakthrough bleeding occurs.
Mitsumasa Osuna +4 more
doaj +2 more sources
Anti-emicizumab antibodies and their relevance in clinical practice [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Emicizumab is licensed for treatment of people with hemophilia A (HA) of all ages, with and without factor (F)VIII inhibitors. It is well tolerated, and most of the treatment-related adverse events are of mild intensity and transient.
Carla Valsecchi +5 more
doaj +2 more sources
Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
BMC Pediatrics, 2022 Purpose Real-world data and study data regarding therapy with Emicizumab in pediatric cohorts with haemophilia A is scarce. Especially, data on previously untreated pediatric patients (PUPs) and minimally treated patients (MTPs) are missing.
Hannah Glonnegger +5 more
doaj +4 more sources
Clinical Experience with Emicizumab and Rituximab as First-Line Treatment in a Case Series of Acquired Hemophilia A [PDF]
Hematology ReportsBackground: Acquired hemophilia A (AHA) is a bleeding disorder caused by autoantibodies against coagulation factor VIII. Treatment includes controlling bleeding and eliminating the inhibitor.
Hikari Ota +3 more
doaj +2 more sources
Research and Practice in Thrombosis and Haemostasis, 2022 Background Emicizumab is a new treatment option for people with hemophilia A. Emicizumab was approved with a body‐weight‐based dosage regimen, without laboratory monitoring requirements.
Moniek De Maat +2 more
exaly +2 more sources
Emicizumab state‐of‐the‐art update
Haemophilia, 2022 AbstractIntroductionEmicizumab is a bispecific monoclonal antibody developed to address the unmet needs of clotting factor replacement therapy and has become the benchmark for optimal prophylaxis in managing patients with haemophilia A with inhibitors.
Johnny Mahlangu +2 more
exaly +4 more sources
Emicizumab prophylaxis in a preterm infant with severe hemophilia A: a case report on the feasibility of early use [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Emicizumab provides effective prophylaxis for hemophilia A (HA), but evidence for preterm and very low-birth-weight infants remains limited. Key Clinical Question: Can emicizumab be safely initiated shortly after birth in a preterm, low-birth-
Eman Hassan +6 more
doaj +2 more sources
Importance of Inhibitor Surveillance During Emicizumab Prophylaxis in Young Children With Hemophilia: An Illustrative Case Series [PDF]
Case Reports in HematologyHemophilia is an X-linked inherited bleeding disorder associated with bleeding, which starts in infancy. The age of initiation of prophylaxis with clotting factor concentrate is limited by the intravenous mode of administration. Emicizumab, a Factor VIII
Kelly A. Bush +3 more
doaj +2 more sources
NXT007 enhances in vitro coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formation [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: NXT007 is a factor (F)VIIIa-mimetic bispecific antibody (BsAb) for hemophilia A (HA), engineered from emicizumab. It is designed to achieve non-hemophiliac levels of plasma coagulation potential and is currently under clinical development. In
Kazuki Yamaguchi +7 more
doaj +2 more sources